Last reviewed · How we verify

NCT04762550

Thrombin Generation in Liver Transplant Surgery

Status unknown Last updated 3 May 2021
What this trial tests

trial in Liver Transplantation in 100 participants. Status unknown.

Timeline
8 March 2021
Primary endpoint
1 January 2022
1 January 2022

Quick facts

Lead sponsorUniversity Health Network, Toronto
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date8 March 2021
Primary completion1 January 2022
Estimated completion1 January 2022
Sites1 location across Canada

Conditions studied

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Liver Transplantation or Thrombin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective observational study of 100 patients undergoing liver transplantation at a single centre. Thrombin generation and kinetics will be assessed using a novel point-of-care device, and compared to conventional measures of hemostasis as well as viscoelastic tests to pinpoint specific coagulation deficits and identify potential therapeutic targets. The clinical course of patients will be followed for major bleeding and transfusion outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Transplantation

Currently open trials in the same condition.

Other University Health Network, Toronto trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04762550.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing